文献速递新发突发、热带与寄生虫病

既往接种两剂异源Ad26.ZEBOV和MVA-BN-Filo埃博拉疫苗方案的儿童中Ad26.ZEBOV加强剂次的安全性和免疫原性:一项开放标签、非随机2期试验

Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
PubMed 文献 · Lancet Infect Dis · 2022-10-20

在塞拉利昂Kambia镇一家诊所开展的开放标签、非随机2期试验中,50名既往接种过两剂Ad26.ZEBOV和MVA-BN-Filo方案的儿童在首剂后超过3年接种Ad26.ZEBOV加强剂。加强剂耐受良好,未观察到严重不良事件,接种后7天和21天埃博拉病毒糖蛋白特异性IgG结合抗体几何平均浓度分别较加强前升高44倍和101倍。

要点

  • 50名儿童接种Ad26.ZEBOV加强剂,最常见征集性局部不良事件为注射部位疼痛(18/50,36%)。
  • 最常见征集性全身不良事件为头痛(11/50,22%),研究期间未观察到严重不良事件。
  • 接种后21天IgG结合抗体几何平均浓度达64 690 ELISA单位/mL,较加强前升高101倍。

核心结论

  • 在首剂后超过3年接种Ad26.ZEBOV加强剂耐受良好,并诱导针对埃博拉病毒结合抗体的快速且稳健升高。
  • 这些发现可为儿童人群的埃博拉疫苗接种策略提供参考。

研究设计与样本

  • 开放标签、非随机2期试验,在塞拉利昂Kambia镇一家诊所开展。
  • 纳入既往研究中接种过Ad26.ZEBOV(第1剂)和MVA-BN-Filo(第2剂)方案、首剂时年龄1-11岁的健康儿童,排除怀孕或哺乳期女孩。
  • 50名儿童(4-7岁27名,9-15岁23名)在2021年7月8日至8月18日入组并接种Ad26.ZEBOV加强剂(5 × 10^10病毒颗粒,肌内注射),随访28天。
  • 安全性分析纳入所有接受加强接种的参与者;免疫原性分析纳入所有接受加强接种、加强后至少有一个可评估样本且无可能影响免疫应答的重大方案偏离的参与者。
  • 试验注册号ClinicalTrials.gov NCT04711356。

主要发现

  • 接种后7天内最常见征集性局部不良事件为注射部位疼痛,50名参与者中报告18名(36%,95% CI 23-51)。
  • 接种后7天内最常见征集性全身不良事件为头痛,50名参与者中报告11名(22%,95% CI 12-36)。
  • 接种后28天内最常见非征集性不良事件为疟疾,50名参与者中报告25名(50%,95% CI 36-64)。
  • 研究期间未观察到严重不良事件。
  • 接种后7天埃博拉病毒糖蛋白特异性IgG结合抗体几何平均浓度为28 561 ELISA单位/mL(95% CI 20 255-40 272),较加强前几何平均浓度升高44倍。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Children account for a substantial proportion of cases and deaths during Ebola virus disease outbreaks. We aimed to evaluate the safety and immunogenicity of a booster dose of the Ad26.ZEBOV vaccine in children who had been vaccinated with a two-dose regimen comprising Ad26.ZEBOV as dose one and MVA-BN-Filo as dose two. METHODS: We conducted an open-label, non-randomised, phase 2 trial at one clinic in Kambia Town, Sierra Leone. Healthy children, excluding pregnant or breastfeeding girls, who had received the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen in a previous study, and were aged 1-11 years at the time of their first vaccine dose, received an intramuscular injection of Ad26.ZEBOV (5 × 1010 viral particles) and were followed up for 28 days. Primary outcomes were safety (measured by adverse events) and immunogenicity (measured by Ebola virus glycoprotein-specific IgG binding antibody geometric mean concentration) of the booster vaccine dose. Safety was assessed in all participants who received the booster vaccination; immunogenicity was assessed in all participants who received the booster vaccination, had at least one evaluable sample after the booster, and had no major protocol deviations that could have influenced the immune response. This trial is registered with ClinicalTrials.gov, NCT04711356. FINDINGS: Between July 8 and Aug 18, 2021, 58 children were assessed for eligibility and 50 (27 aged 4-7 years and 23 aged 9-15 years) were enrolled and received an Ad26.ZEBOV booster vaccination, more than 3 years after receiving dose one of the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen. The booster was well tolerated. The most common solicited local adverse event during the 7 days after vaccination was injection site pain, reported in 18 (36%, 95% CI 23-51) of 50 participants. The most common solicited systemic adverse event during the 7 days after vaccination was headache, reported in 11 (22%, 12-36) of 50 participants. Malaria was the most common unsolicited adverse event during the 28 days after vaccination, reported in 25 (50%, 36-64) of 50 participants. No serious adverse events were observed during the study period. 7 days after vaccination, the Ebola virus glycoprotein-specific IgG binding antibody geometric mean concentration was 28 561 ELISA units per mL (95% CI 20 255-40 272), which was 44 times higher than the geometric mean concentration before the booster dose. 21 days after vaccination, the geometric mean concentration reached 64 690 ELISA units per mL (95% CI 48 356-86 541), which was 101 times higher than the geometric mean concentration before the booster dose. INTERPRETATION: A booster dose of Ad26.ZEBOV in children who had received the two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen more than 3 years earlier was well tolerated and induced a rapid and robust increase in binding antibodies against Ebola virus. These findings could inform Ebola vaccination strategies in paediatric populations. FUNDING: Innovative Medicines Initiative 2 Joint Undertaking. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Manno D, Bangura A, Baiden F, et al. Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial. Lancet Infect Dis. 2022. PMID: 36273490. doi:10.1016/S1473-3099(22)00594-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。